Jozwiak Marta, Dodd Jodie M
Leiden University Medical Center, Leiden, Netherlands.
Cochrane Database Syst Rev. 2013 Mar 28(3):CD009792. doi: 10.1002/14651858.CD009792.pub2.
Induction of labour is a common obstetric intervention, with between 20% and 30% of births reported to occur following induction of labour. Women with a prior caesarean delivery have an increased risk of uterine rupture, particularly when labour is induced. For women who have had a previous caesarean birth and who require induction of labour in a subsequent pregnancy, it is unclear which method of cervical ripening and labour induction is preferable.
To assess the benefits and harms associated with different methods used to induce labour in women who have had a previous caesarean birth and require induction of labour in a subsequent pregnancy.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 July 2012) and reference lists of retrieved studies.
All randomised controlled trials comparing any method of third trimester cervical ripening or labour induction, with placebo/no treatment or other methods in women with prior caesarean section requiring labour induction in a subsequent pregnancy were included.Methods of cervical ripening or labour induction could include: prostaglandin medication (including oral or vaginal prostaglandin E2 (PGE2) and misoprostol); mifepristone; mechanical methods (including Foley catheters and double balloon catheters); oxytocin, or placebo.
The two review authors independently assessed studies for inclusion and trial quality. Any disagreement was resolved by discussion. Both review authors independently extracted data and data were checked for accuracy.
Two studies (involving a total of 80 women) were included. However, the two included studies used different methods and thus, meta-analysis was not appropriate. The two included studies compared 2.5 mg vaginal PGE2 inserts versus oxytocin (Taylor and colleagues) and misoprostol versus oxytocin (Wing and colleagues). Risk of bias in the included studies was judged 'low' and 'unclear' respectively.Vaginal PGE2 inserts versus oxytocin - Taylor and colleagues included 42 women, equally distributed over both groups. Baseline characteristics, and reasons for labour induction were comparable between the groups. There were no significant differences in any of the outcome measures reported (caesarean section, instrumental vaginal deliveries, epidural analgesia, Apgar score, perinatal death). One uterine rupture occurred in the prostaglandin group, after the use of prostaglandins and oxytocin, while no ruptures occurred in the oxytocin group (one study, 42 women; risk ratio (RR) 3.00, 95% confidence interval (CI) 0.13 to 69.70).Misoprostol versus oxytocin - the study conducted by Wing and colleagues was stopped prematurely due to safety concerns after the inclusion of 38 women. Seventeen women had been included in the misoprostol group, and 21 women in the oxytocin group. There were no significant difference in the only outcome measure reported by the authors, uterine rupture, which occurred twice in the misoprostol group, and did not occur in the oxytocin group (one study; 38 women; RR 6.11, 95% CI 0.31 to 119.33).
AUTHORS' CONCLUSIONS: There is insufficient information available from randomised controlled trials on which to base clinical decisions regarding the optimal method of induction of labour in women with a prior caesarean birth.
引产是一种常见的产科干预措施,据报道,20%至30%的分娩是在引产之后发生的。有剖宫产史的女性发生子宫破裂的风险增加,尤其是在引产时。对于有剖宫产史且在后续妊娠中需要引产的女性,尚不清楚哪种宫颈成熟和引产方法更可取。
评估在有剖宫产史且在后续妊娠中需要引产的女性中,不同引产方法的益处和危害。
我们检索了Cochrane妊娠与分娩组试验注册库(2012年7月31日)以及检索到的研究的参考文献列表。
纳入所有比较任何孕晚期宫颈成熟或引产方法与安慰剂/不治疗或其他方法的随机对照试验,这些试验的对象是有剖宫产史且在后续妊娠中需要引产的女性。宫颈成熟或引产方法可包括:前列腺素药物(包括口服或阴道用前列腺素E2(PGE2)和米索前列醇);米非司酮;机械方法(包括Foley导管和双球囊导管);缩宫素,或安慰剂。
两位综述作者独立评估研究是否纳入以及试验质量。任何分歧通过讨论解决。两位综述作者独立提取数据,并检查数据的准确性。
纳入了两项研究(共涉及80名女性)。然而,这两项纳入的研究使用了不同的方法,因此,荟萃分析并不合适。这两项纳入的研究分别比较了2.5毫克阴道用PGE2栓剂与缩宫素(泰勒及其同事)以及米索前列醇与缩宫素(温及其同事)。纳入研究中的偏倚风险分别被判定为“低”和“不清楚”。
阴道用PGE2栓剂与缩宫素——泰勒及其同事的研究纳入了42名女性,两组人数均等。两组的基线特征和引产原因具有可比性。所报告的任何结局指标(剖宫产、器械助产阴道分娩、硬膜外镇痛、阿氏评分、围产儿死亡)均无显著差异。前列腺素组在使用前列腺素和缩宫素后发生了1例子宫破裂,而缩宫素组未发生破裂(一项研究,42名女性;风险比(RR)3.00,95%置信区间(CI)0.13至69.70)。
米索前列醇与缩宫素——温及其同事进行的研究在纳入3